Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
FBO DAILY - FEDBIZOPPS ISSUE OF NOVEMBER 10, 2017 FBO #5831
SOLICITATION NOTICE

66 -- E. coli prebank testing, master cell banking and working cell bank

Notice Date
11/8/2017
 
Notice Type
Presolicitation
 
NAICS
325414 — Biological Product (except Diagnostic) Manufacturing
 
Contracting Office
Department of Health and Human Services, National Institutes of Health, National Institute of Allergy & Infectious Diseases/AMOB, 5601 Fishers Lane, 3rd Floor MSC 9822, Bethesda, Maryland, 20892, United States
 
ZIP Code
20892
 
Solicitation Number
NOI-RML-D-1878336
 
Archive Date
12/2/2017
 
Point of Contact
Skye Duffner, Phone: 4068026092, Julienne Keiser, Phone: 406-363-9370
 
E-Mail Address
skye.duffner@nih.gov, jkeiser@niaid.nih.gov
(skye.duffner@nih.gov, jkeiser@niaid.nih.gov)
 
Small Business Set-Aside
N/A
 
Description
This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with Charles River Laboratory, Wilmington, MA to procure the service of cell production and master and working cell banking. The manufacturing and testing of these cells will be used in support of ongoing research at the Laboratory of Malaria Immunology and Vaccinology (LMIV) to research, pursue, produce and clinical trial malaria vaccines. Place of Performance is Rockville, MD 20852. Charles River Laboratories has produced the master and working cell banks for LMIV for the production of cGMP grade malaria vaccines at the NCI's BDP manufacturing plant. CRL has undergone an audit and were found to be in full compliance with cGMP and FDA standards. CRL has separate facilities for microbial and yeast cell banking to reduce the risk of contamination. We require that the manufacturing and testing of the cGMP cell banks to be performed to the standards as required by the FDA for inclusion in investigational new drug (IND) applications which is the review document we must submit to the FDA prior to human testing in a Clinical trial. The statutory authority for this sole source requirement is 41 U.S.C. 253 (c) (1) as implemented by FAR 6.302-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI-RML-D-1878336) to Skye Duffner at skye.duffner@nih.gov by 5:00 pm eastern standard time, Friday, November 17, 2017. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.
 
Web Link
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/AMOB/NOI-RML-D-1878336/listing.html)
 
Place of Performance
Address: 5640 Fishers Lane, Rockville, Maryland, 20852, United States
Zip Code: 20852
 
Record
SN04735540-W 20171110/171108231129-8f38a1894e6cb5d86d692643c6bcdced (fbodaily.com)
 
Source
FedBizOpps Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.